Jennifer E. Cook

CIK: 0001754371

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (27.3%)

Position reduction

Option Exercises (M)7 (31.8%)

Derivative conversions

Awards (A)6 (27.3%)

Compensation grants

Other (G, F, J, C, D, …)3 (13.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

JAZZ

Jazz Pharmaceuticals plc

Director

BBIO

BridgeBio Pharma, Inc.

Director

DNLI

Denali Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (22 total)

JAZZ
Jazz Pharmaceuticals plc
Aug 31, 2026
Tax Payment(F)
Direct
1.7K shares at avg. $241.39$408K
JAZZ
Jazz Pharmaceuticals plc
Aug 31, 2026
Tax Payment(F)
Direct
14 shares at avg. $244.06$3K
JAZZ
Jazz Pharmaceuticals plc
Aug 5, 2026
Award(A)
Direct
1.6K shares-
BBIO
BridgeBio Pharma, Inc.
Jul 9, 2026
Exercise(M)
Direct
17.2K shares at avg. $16.75$288K
BBIO
BridgeBio Pharma, Inc.
Jul 9, 2026
Sale(S)
Direct
36.2K shares at avg. $84.00$3.0M
BBIO
BridgeBio Pharma, Inc.
Jul 9, 2026
Sale(S)
Direct
112.4K shares at avg. $90.00$10.1M
BBIO
BridgeBio Pharma, Inc.
Jul 9, 2026
Exercise(M)
Direct
112.4K shares at avg. $29.00$3.3M
BBIO
BridgeBio Pharma, Inc.
Jul 9, 2026
Exercise(M)
Direct
19K shares at avg. $8.45$161K
BBIO
BridgeBio Pharma, Inc.
Jun 24, 2026
Exercise(M)
Direct
20K shares at avg. $8.45$169K
BBIO
BridgeBio Pharma, Inc.
Jun 24, 2026
Exercise(M)
Direct
17.2K shares at avg. $16.75$288K
BBIO
BridgeBio Pharma, Inc.
Jun 24, 2026
Sale(S)
Direct
37.2K shares at avg. $70.00$2.6M
BBIO
BridgeBio Pharma, Inc.
Jun 23, 2026
Sale(S)
Direct
2.2K shares at avg. $68.57$151K
BBIO
BridgeBio Pharma, Inc.
Jun 22, 2026
Award(A)
Direct
4K shares-
BBIO
BridgeBio Pharma, Inc.
Jun 15, 2026
Exercise(M)
Direct
65.9K shares at avg. $8.45$557K
BBIO
BridgeBio Pharma, Inc.
Jun 15, 2026
Exercise(M)
Direct
17.2K shares at avg. $16.75$288K
BBIO
BridgeBio Pharma, Inc.
Jun 15, 2026
Sale(S)
Direct
88.7K shares at avg. $66.62$5.9M
BBIO
BridgeBio Pharma, Inc.
Jun 15, 2026
Sale(S)
Direct
1.5K shares at avg. $67.14$101K
DNLI
Denali Therapeutics Inc.
Jun 3, 2026
Award(A)
Direct
6.4K shares-
JAZZ
Jazz Pharmaceuticals plc
Aug 8, 2025
Tax Payment(F)
Direct
1.8K shares at avg. $111.25$201K
JAZZ
Jazz Pharmaceuticals plc
Aug 7, 2025
Award(A)
Direct
3.5K shares-
BBIO
BridgeBio Pharma, Inc.
Jun 20, 2025
Award(A)
Direct
6.6K shares-
DNLI
Denali Therapeutics Inc.
Jun 3, 2025
Award(A)
Direct
6K shares-

		Type	Shares	Price		Ownership
Aug 31, 2026	JAZZ Jazz Pharmaceuticals plc	Tax Payment(F)	1,692	$241.39	$408,432	Direct
Aug 31, 2026	JAZZ Jazz Pharmaceuticals plc	Tax Payment(F)	14	$244.06	$3,417	Direct
Aug 5, 2026	JAZZ Jazz Pharmaceuticals plc	Award(A)	1,605	-	$0	Direct
Jul 9, 2026	BBIO BridgeBio Pharma, Inc.	Exercise(M)	17,167	$16.75	$287,547	Direct
Jul 9, 2026	BBIO BridgeBio Pharma, Inc.	Sale(S)	36,167	$84.00	$3,038,028	Direct
Jul 9, 2026	BBIO BridgeBio Pharma, Inc.	Sale(S)	112,422	$90.00	$10,117,980	Direct
Jul 9, 2026	BBIO BridgeBio Pharma, Inc.	Exercise(M)	112,422	$29.00	$3,260,238	Direct
Jul 9, 2026	BBIO BridgeBio Pharma, Inc.	Exercise(M)	19,000	$8.45	$160,550	Direct
Jun 24, 2026	BBIO BridgeBio Pharma, Inc.	Exercise(M)	20,000	$8.45	$169,000	Direct
Jun 24, 2026	BBIO BridgeBio Pharma, Inc.	Exercise(M)	17,167	$16.75	$287,547	Direct
Jun 24, 2026	BBIO BridgeBio Pharma, Inc.	Sale(S)	37,167	$70.00	$2,601,690	Direct
Jun 23, 2026	BBIO BridgeBio Pharma, Inc.	Sale(S)	2,196	$68.57	$150,580	Direct
Jun 22, 2026	BBIO BridgeBio Pharma, Inc.	Award(A)	3,990	-	$0	Direct
Jun 15, 2026	BBIO BridgeBio Pharma, Inc.	Exercise(M)	65,921	$8.45	$557,032	Direct
Jun 15, 2026	BBIO BridgeBio Pharma, Inc.	Exercise(M)	17,167	$16.75	$287,547	Direct
Jun 15, 2026	BBIO BridgeBio Pharma, Inc.	Sale(S)	88,737	$66.62	$5,911,242	Direct
Jun 15, 2026	BBIO BridgeBio Pharma, Inc.	Sale(S)	1,503	$67.14	$100,915	Direct
Jun 3, 2026	DNLI Denali Therapeutics Inc.	Award(A)	6,408	-	$0	Direct
Aug 8, 2025	JAZZ Jazz Pharmaceuticals plc	Tax Payment(F)	1,805	$111.25	$200,805	Direct
Aug 7, 2025	JAZZ Jazz Pharmaceuticals plc	Award(A)	3,507	-	-	Direct
Jun 20, 2025	BBIO BridgeBio Pharma, Inc.	Award(A)	6,589	-	-	Direct
Jun 3, 2025	DNLI Denali Therapeutics Inc.	Award(A)	6,037	-	-	Direct

1-22 of 22 transactions

About Cook Jennifer E.

Cook Jennifer E. (SEC CIK 0001754371) files insider reports with the SEC as Director of Jazz Pharmaceuticals plc (JAZZ), Director of BridgeBio Pharma, Inc. (BBIO) and Director of Denali Therapeutics Inc. (DNLI).

Signal8 holds 9 ownership filings by Cook Jennifer E., all Form 4s, filed between Jun 5, 2025 and Sep 2, 2026. Those filings report 22 transactions, from Jun 3, 2025 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cook Jennifer E.'s filings is in DUBLIN 4.

Recent filings by Cook Jennifer E.

Aug 31, 2026: Tax withholdings of JAZZ shares (2 lines, Form 4, code F).
Aug 5, 2026: Grant or award of JAZZ shares (Form 4, code A).
Jul 9, 2026: Option exercise of BBIO shares (Form 4, code M).
Jul 9, 2026: Open-market sales of BBIO shares (2 lines, Form 4, code S).
Jul 9, 2026: Option exercises of BBIO shares (2 lines, Form 4, code M).

Other insiders filing for Jazz Pharmaceuticals plc (JAZZ)

GALA RENEE D, President & CEO
COZADD BRUCE C, Director
Patil Neena M, EVP & Chief Legal Officer
Henderson Mary Elizabeth, SVP, Technical Operations
Smith Mark Douglas, Director
RIEDEL NORBERT G, Director

How to read Form 4 transaction codes